Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells

Biochemical Pharmacology

Volumn 52, Issue 4, 1996, Pages 635-642

  Fattman, Cheryl L ^a   Allan, William P ^a   Hasinoff, Brian B ^c   Yalowich, Jack C ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

bisdioxopiperazines; etoposide; ICRF 187; K562 cells; topoisomerase II

Indexed keywords

ETOPOSIDE; FOSTRIECIN; GYRASE INHIBITOR; MERBARONE; RAZOXANE;

ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DNA BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL;

EID: 0029982836     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00338-3     Document Type: Article

References (47)

1. Wang JC, DNA topoisomerases. Annu Rev Biochem 54: 665-697, 1985.
2. Osheroff N, Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther 41: 223-241, 1989.
3. Liu LF, DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
4. Zhang H, D'Arpa P and Liu LF, A model for tumor cell killing by topoisomerase poisons. Cancer Cells 2: 23-27, 1990.
5. Zwelling LA, DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metastasis Rev 4: 263-276, 1985.
6. Osheroff N, Corbett AH and Robinson MJ, Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv Pharmacol 29B: 105-126, 1994.
7. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM and Liu LF, Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259: 13560-13566, 1984.
8. Nelson EM, Tewey KM and Liu LF, Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acrinylamino)methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81: 1361-1365, 1984.
9. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST and Mirabelli CK, Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem 262: 16739-16747, 1987.
10. Webb CD, Latham MD, Lock RB and Sullivan DM, Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51: 6542-6549, 1991.
11. Cole SPC, Chanda EP, Dickle FP, Gerlach JH and Mirski SEL, Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51: 3345-3352, 1991.
12. Long BH, Wang L, Lorico A, Wang RCC, Brattain MG and Casazza AM, Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 51: 5275-5284, 1991.
13. Ritke MK and Yalowich JC, Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol 46: 2007-2020, 1993.
14. Ferguson PJ, Fisher MH, Stephenson J, Li D-H, Zhou B-S and Cheng Y-C, Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48: 5956-5964, 1988.
15. Matsuo K, Kohno K, Takano H, Sato S, Kiue A and Kuwano M, Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Cancer Res 50: 5819-5824, 1990.
16. Kamath N, Grabowski D, Ford J, Kerrigan D, Pommier Y and Ganapathi R, Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Biochem Pharmacol 44: 937-945, 1992.
17. Schneider E, Horton JK, Yang C-H, Nakagawa M and Cowan KH, Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54: 152-158, 1994.
18. Hasegawa S, Abe T, Naito S, Kotoh S, Kumanzawa J, Hipfner DR, Deeley RG, Cole SPC and Kuwano M, Expression of multidrug resistance-associated protein (MRP).MDR-1, and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 71: 907-913, 1995.
19. Danks MK, Schmidt CA, Cirtain MC, Suttle DP and Beck WT, Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861-8869, 1988.
20. Sullivan DM, Latham MD, Rowe TC and Ross WE, Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry 28: 5680-5687, 1989.
21. Zwelling LA, Hinds M, Chan D, Mayes J, LanSie K, Parker E, Silberman L, Radcliffe A, Beran M and Blick M, Characterization of an amsacrine-resistant line of human leukemia cells: Evidence for a drug-resistant form of topoisomerase II. J Biol Chem 264: 16411-16420, 1989.
22. Sullivan DM, Eskildsen L, Groom KR, Webb CD, Latham MD, Martin AW, Wellhausen SR, Kroeger PE and Rowe TC, Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Mol Pharmacol 43: 207-216, 1993.
23. Campain JA, Padmanabhan R, Hwang J, Gottesman MM and Pastan I, Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. J Cell Physiol 155: 414-425, 1993.
24. Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV and Yalowich JC, Altered stability of etoposide-induced topoisomerase II/DNA complexes in resistant human leukemia cells. Br J Cancer 69: 687-697, 1994.
25. Ritke MK, Allan WP, Fattman CL, Gunduz NN and Yalowich JC, Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol Pharmacol 46: 58-66, 1994.
26. II protein kinase C. Mol Pharmacol 48: 798-806, 1995.
27. Drake FH, Hofmann GA, Mong S-M, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR and Mirabelli CK, In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49: 2578-2583, 1989.
28. Boritzki TJ, Wolfard TS, Besser JA, Jackson RC and Fry DW, Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 37: 4063-4068, 1988.
29. Jensen PB, Sorensen BS, Sehested M, Demant EJ, Kjeldsen E, Friche E and Hansen HH, Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA cleavage and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 45: 2025-2035, 1993.
30. Tanabe K, Ikegami Y, Ishida R and Andoh T, Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51: 4903-4908, 1991.
31. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K and Andoh T, Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51: 4909-4916, 1991.
32. Roca J, Ishida R, Berger JM, Andoh T and Wang JC, Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91: 1781-1785, 1994.
33. Gorbsky GJ, Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane; ADR-529] and ICRF-159 (Razoxane). Cancer Res 54: 1042-1048, 1994.
34. Chen M and Beck WT, Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 53: 5946-5953, 1993.
35. 2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res 55: 1509-1516, 1995.
36. Wasserman RA and Wang JC, Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. Implications in resistance to multiple antitumor drugs targeting the enzyme. J Biol Chem 269: 20943-20951, 1994.
37. Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC and Andoh T, DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55: 2299-2303, 1995.
38. Sahai BM and Kaplan JG, A quantitative decatenation assay for type II topoisomerases. Anal Biochem 156: 364-379, 1986.
39. Yalowich JC, Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro. Cancer Res. 47: 1010-1015, 1987.
40. Yalowich JC and Goldman ID, Analysis of the inhibitory effects of VP-16-213 (etoposide) by podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro. Cancer Res. 44: 984-989, 1984.
41. Sehested M, Jensen PB, Sørensen BS, Holm B, Friche E and Demant EJF, Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopeperazinyl-l-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46: 389-393, 1993.
42. Hasinoff BB, Kuschak TI, Yalowich JC and Creighton AM, A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50: 953-958, 1995.
43. Roca J and Wang JC, The capture of a DNA double helix by an ATP-dependent protein clamp: A key step in DNA transport by type II DNA topoisomerases. Cell 71: 833-840, 1992.
44. Jensen PB, Sorensen BS, Demant EJF, Sehested M, Jensen PS, Vindelov L and Hansen HH, Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino) methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 49: 2578-2583, 1988.
45. Roberge M, Tudan C, Hung SMF, Harder KW, Jirik FR and Anderson H, Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 54: 6115-6121, 1994.
46. de Jong S, Zijlstra JG, Mulder NH and de Vries EGE, Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol 28: 461-464, 1991.
47. Fernandes DJ, Smith-Nanni C, Paff MT and Neff T-AM, Effects of antileukemia agents on nuclear matrix-bound DNA replication in CCRF-CEM leukemia cells. Cancer Res 48: 1850-1855, 1988.